Nalmefene for the treatment of alcohol dependence: A current update

International Journal of Neuropsychopharmacology

Volumn 17, Issue 4, 2014, Pages 675-684

  Soyka, Michael ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Privatklinik Meiringen ^*  (Switzerland)

Author keywords

Alcohol; alcoholism; nalmefene; opioid antagonists; opioid receptors

Indexed keywords

NALMEFENE; PLACEBO; NALTREXONE; NARCOTIC ANTAGONIST;

ALCOHOLISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; HUMAN; MULTICENTER STUDY (TOPIC); NEUROBIOLOGY; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES;

ALCOHOLISM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 84896388884     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001284     Document Type: Review

References (116)

1. Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD (2006) Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron 50:507-517.
2. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24:421-428.
3. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135-144.
4. Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A (2012) Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res 36:2000-2007.
5. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Makela R, Kranzler HR (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 32:1159-1166.
6. Ashenhurst JR, Bujarski S, Ray LA (2012) Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav 103:253-259.
7. Aubin HJ, Daeppen JB (2013) Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug Alcohol Depend 133:15-29.
8. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M (2007) Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 64:369-376.
9. Barson JR, Carr AJ, Soun JE, Sobhani NC, Rada P, Leibowitz SF, Hoebel BG (2010) Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. Alcohol Clin Exp Res 34:214-222.
10. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005a) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30:2254-2262.
11. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M (2005b) Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30:417-422.
12. Belluzzi JD, Stein L (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature 266:556-558.
13. Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF, Frost JJ (2004) Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55:255-262.
14. Berglund M, Thelander S, Jonsson E (2003) Treating alcohol and drug abuse: an evidence based review. Weinheim: Wiley-VCH.
15. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613.
16. Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A (2012) Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des 18:5994-6004.
17. Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ (2012) Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 17:505-512.
18. Chen F, Lawrence AJ (2000) Effect of chronic ethanol and withdrawal on the mu-opioid receptor-and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35) S]Guanosine-5′-O-(3-thio)triphosphate in the fawn-hooded rat brain: a quantitative autoradiography study. J Pharmacol Exp Ther 293:159-165.
19. Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27:391-399.
20. Cowen MS, Lawrence AJ (1999) The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 23:1171-1212.
21. Cowen MS, Lawrence AJ (2001) Alterations in central preproenkephalin mRNA expression after chronic free-choice ethanol consumption by fawn-hooded rats. Alcohol Clin Exp Res 25:1126-1133.
22. Dai X, Thavundayil J, Gianoulakis C (2005) Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res 29:1965-1975.
23. Davies DL, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J, Olsen RW (2013) Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res 37:8-15.
24. DeHaven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV, Mavunkel BJ, Rzeszotarski WJ, Steranka LR (1990) Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497-504.
25. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233-239.
26. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28:755-764.
27. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362-1370.
28. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
29. Emsley E, Lees R, Lingford-Hughes A, Nutt D (2013) A review of stress and endogenous opioid interaction in alcohol addiction. J Neurol Neurosurg Psychiatry 84:e1.
30. Erbs E, Faget L, Scherrer G, Kessler P, Hentsch D, Vonesch JL, Matifas A, Kieffer BL, Massotte D (2012) Distribution of delta opioid receptor-expressing neurons in the mouse hippocampus. Neuroscience 221:203-213.
31. European Medicines Agency (2010) Guideline on the development of medicinal products for the treatment of alcohol dependence. London: European Medicines Agency.
32. European Medicines Agency (2013) Selincro (Nalmefene) product information. EMEA/HIL/002583-IAIN10002.
33. Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40:537-542.
34. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31:555-563.
35. Gianoulakis C (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4:39-50.
36. Goeders NE, Lane JD, Smith JE (1984) Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 20:451-455.
37. Grant BF, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Pickering RP (2004) Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:361-368.
38. Gual A, He Y, Torup L, van den Brink W, Mann K (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. doi: 10.1016/j. euroneuro.2013.02.006.
39. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855-876.
40. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DF, Schumann G, Machulla HJ, Bares R, Mann K (2005) Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57-64.
41. Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129:99-111.
42. Hester RK, Miller WR (1995) Handbook of alcoholism treatment approaches: effective alternatives. Boston: Allyn & Bacon.
43. Hiller JM, Zhang Y, Bing G, Gioannini TL, Stone EA, Simon EJ (1994) Immunohistochemical localization of mu-opioid receptors in rat brain using antibodies generated against a peptide sequence present in a purified mu-opioid binding protein. Neuroscience 62:829-841.
44. Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD (1986) Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 3:39-54.
45. Hubbell CL, Abelson ML, Burkhardt CA, Herlands SE, Reid LD (1988) Constant infusions of morphine and intakes of sweetened ethanol solution among rats. Alcohol 5:409-415.
46. Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H (2005) Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30:2245-2253.
47. Jarjour S, Bai L, Gianoulakis C (2009) Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol Clin Exp Res 33:1033-1043.
48. Job MO, Tang A, Hall FS, Sora I, Uhl GR, Bergeson SE, Gonzales RA (2007) Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry 62:627-634.
49. June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A, McCane S, Williams LS, Mason D, Cummings R, Lawrence A (1998) The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 22:2174-2185.
50. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Makela R (2007) Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 31:1179-1187.
51. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
52. Kim S, Wagner HN Jr., Villemagne VL, Kao PF, Dannals RF, Ravert HT, Joh T, Dixon RB, Civelek AC (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med 38:1726-1731.
53. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 201:611-618.
54. Koller G, Zill P, Rujescu D, Ridinger M, Pogarell O, Fehr C, Wodarz N, Bondy B, Soyka M, Preuss UW (2012) Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms. Alcohol Clin Exp Res 36:1230-1236.
55. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
56. Koob GF, Le Moal M (2006) Neurobiology of addiction. Amsterdam; Boston: Elsevier/Academic Press.
57. Koob GF, Roberts AJ, Kieffer BL, Heyser CJ, Katner SN, Ciccocioppo R, Weiss F (2003) Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. Recent Dev Alcohol 16:263-281.
58. Kranzler HR, Armeli S, Covault J, Tennen H (2013) Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol 18:193-201.
59. Kuhar MJ, Pert CB, Snyder SH (1973) Regional distribution of opiate receptor binding in monkey and human brain. Nature 245:447-450.
60. Laramee P, Kusel J, Leonard S, Aubin HJ, Francois C, Daeppen JB (2013) The economic burden of alcohol dependence in Europe. Alcohol Alcohol 48:259-269.
61. Littleton J, Zieglgansberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12 (Suppl. 1): S3-S11.
62. Lotsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82-89.
63. Magill M, Ray LA (2009) Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 70:516-527.
64. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275-293.
65. Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, Anton RF (2012) Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. doi: 10.1111/adB.12012.
66. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706-713.
67. Marinelli PW, Quirion R, Gianoulakis C (2004) An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience 127:777-784.
68. Marinelli PW, Bai L, Quirion R, Gianoulakis C (2005) A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res 29:1821-1828.
69. Marinelli PW, Lam M, Bai L, Quirion R, Gianoulakis C (2006) A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res 30:982-990.
70. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162-1167.
71. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719-724.
72. Matz J, Graff C, Vainio PJ, Kallio A, Hojer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E (2011) Effect of nalmefene 20 and 80mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo-and moxifloxacin-controlled, single-centre study. Clin Drug Investig 31:799-811.
73. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30:1288-1296.
74. Michel ME, Bolger G, Weissman BA (1985) Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175-177.
75. Miller WR, Wilbourne PL (2002) Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 97:265-277.
76. Narita M, Funada M, Suzuki T (2001) Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 89:1-15.
77. Niciu MJ, Arias AJ (2013) Targeted Opioid Receptor Antagonists in the treatment of Alcohol Use Disorders. CNS Drugs. doi: 10.1007/S40263-013-0096-4.
78. Nishizawa D, Han W, Hasegawa J, Ishida T, Numata Y, Sato T, Kawai A, Ikeda K (2006) Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 53:137-141.
79. Oroszi G, Anton RF, O'Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383-393.
80. Osborn MD, Lowery JJ, Skorput AG, Giuvelis D, Bilsky EJ (2010) In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci 86:624-630.
81. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552.
82. Oswald LM, Wand GS (2004) Opioids and alcoholism. Physiol Behav 81:339-358.
83. Pirkola SP, Poikolainen K, Lonnqvist JK (2006) Currently active and remitted alcohol dependence in a nationwide adult general population-results from the Finnish Health 2000 study. Alcohol Alcohol 41:315-320.
84. Prendergast M, Podus D, Finney J, Greenwell L, Roll J (2006) Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 101:1546-1560.
85. Project MATCH Research Group (1997) Project MATCH secondary a priori hypotheses. Addiction 92:1671-1698.
86. Przewlocka B, Turchan J, Lason W, Przewlocki R (1997) Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett 238:13-16.
87. Rehm J, Room R, van den Brink W, Jacobi F (2005) Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 15:377-388.
88. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373:2223-2233.
89. Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, Parry CD, Patra J, Popova S, Poznyak V, Roerecke M, Room R, Samokhvalov AV, Taylor B (2010) The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 105:817-843.
90. Rehm J, Shield KD, Gmel G, Rehm MX, Frick U (2013) Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. European Neuropsychopharmacology 23:89-97.
91. Reid LD (1996) Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Alcohol 13:5-11.
92. Rosin A, Lindholm S, Franck J, Georgieva J (1999) Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci Lett 275:1-4.
93. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010a) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. doi: 10.1002/14651858. CD001867.
94. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010b) Acamprosate for alcohol dependence. Cochrane Database Syst Rev doi: 10.1002/14651858. CD004332.
95. Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H (2013) Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology 38:414-422.
96. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A, Kreek MJ (1998) Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res 22:1430-1436.
97. Setiawan E, Pihl RO, Benkelfat C, Leyton M (2012) Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics 13:1161-1172.
98. Somogyi AA, Barratt DT, Coller JK (2007) Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429-444.
99. Soyka M (2013) Update alcohol dependence. Bremen: Unimed Verlag.
100. Soyka M, Kuefner H (2008) Alcoholism-abuse and dependence. Stuttgart: Thieme.
101. Soyka M, Rosner S (2010) Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs 15:695-711.
102. Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, Moller HJ (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry 9:6-23.
103. Spanagel R (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89:649-705.
104. Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29:109-115.
105. Spanagel R, Vengeliene V (2013) New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 13:583-609.
106. Swift RM (2013) Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry 73:700-701.
107. Turchan J, Przewlocka B, Toth G, Lason W, Borsodi A, Przewlocki R (1999) The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 91:971-977.
108. Unterwald EM, Tsukada H, Kakiuchi T, Kosugi T, Nishiyama S, Kreek MJ (1997) Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain. Brain Res 775:183-188.
109. van den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K (2013) Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol and alcoholism 48:570-578.
110. van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van Breukelen GJ (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 31:1-10.
111. Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643-652.
112. Walker BM, Zorrilla EP, Koob GF (2011) Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol 16:116-119.
113. Walker BM, Valdez GR, McLaughlin JP, Bakalkin G (2012) Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol 46:359-370.
114. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679.
115. World Health Organization (2011) Global status report on alcohol and health. Geneva: WHO Press.
116. Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L, Goate A, Bucholz K, Schuckit M, Nurnberger J Jr., Tischfield J, Kuperman S, Porjesz B, Begleiter H, Foroud T, Edenberg HJ (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11: 1016-1024.